Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Biotech Bucks Trend, Gets Funds Infusion

This article was originally published in PharmAsia News

Executive Summary

Australia's HealthLinx biotech said it has been able to do what other biotechs have found hard to obtain - a U.S.$2.1 million infusion of funds to help develop its diagnostics. The managing director said the funding from Copulos Group, its largest shareholder, would allow HealthLinx to continue working on its initiatives. The firm already has its OvPlex diagnostic on the Australian market for detecting early-stage ovarian cancer. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071167

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel